RU2011151611A - Композиции для модуляции киназного каскада и способы их применения - Google Patents
Композиции для модуляции киназного каскада и способы их применения Download PDFInfo
- Publication number
- RU2011151611A RU2011151611A RU2011151611/04A RU2011151611A RU2011151611A RU 2011151611 A RU2011151611 A RU 2011151611A RU 2011151611/04 A RU2011151611/04 A RU 2011151611/04A RU 2011151611 A RU2011151611 A RU 2011151611A RU 2011151611 A RU2011151611 A RU 2011151611A
- Authority
- RU
- Russia
- Prior art keywords
- polymorph
- dsc
- acetone
- morpholinoethoxy
- pyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/59—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with at least one of the bonds being to sulfur
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
1. Полиморф мезилатной соли 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-N-бензилацетамида (Форма A), характеризующийся структурой дифракции рентгеновских лучей, в основном подобной представленной на фиг.7.2. Полиморф мезилатной соли 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-N-бензилацетамида (Форма A), характеризующийся структурой дифракции рентгеновских лучей, включающей пики в приблизительно 22,7, 19,7, 18,9 и 16,3 градусов 2θ.3. Полиморф мезилатной соли 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-N-бензилацетамида (Форма A), характеризующийся термограммой дифференциальной сканирующей калориметрии (DSC), имеющей единственное максимальное значение при приблизительно 164 при измерении прибором Mettler 822DSC.4. Полиморф по п.1, дополнительно характеризующийся термограммой дифференциальной сканирующей калориметрии (DSC), имеющей единственное максимальное значение при приблизительно 164 при измерении прибором Mettler 822DSC.5. Полиморф по п.2, дополнительно характеризующийся термограммой дифференциальной сканирующей калориметрии (DSC), имеющей единственное максимальное значение при приблизительно 164 при измерении прибором Mettler 822DSC.6. Полиморф по любому из пп.1-5, полученный способом очистки, включающим стадию перекристаллизации сырого препарата указанной соли из ацетона.7. Полиморф по п.6, причем количество указанного используемого ацетона составляет более чем 64 объема.8. Фармацевтическая композиция, включающая полиморф по п.6 и фармацевтически приемлемый эксципиент или носитель.9. Способ лечения или профилактики заболевания или состояния у пациента, включающий стадия введения указанному пациенту фармацевтической композиции по п.8, причем указан
Claims (13)
1. Полиморф мезилатной соли 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-N-бензилацетамида (Форма A), характеризующийся структурой дифракции рентгеновских лучей, в основном подобной представленной на фиг.7.
2. Полиморф мезилатной соли 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-N-бензилацетамида (Форма A), характеризующийся структурой дифракции рентгеновских лучей, включающей пики в приблизительно 22,7, 19,7, 18,9 и 16,3 градусов 2θ.
3. Полиморф мезилатной соли 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-N-бензилацетамида (Форма A), характеризующийся термограммой дифференциальной сканирующей калориметрии (DSC), имеющей единственное максимальное значение при приблизительно 164 при измерении прибором Mettler 822e DSC.
4. Полиморф по п.1, дополнительно характеризующийся термограммой дифференциальной сканирующей калориметрии (DSC), имеющей единственное максимальное значение при приблизительно 164 при измерении прибором Mettler 822e DSC.
5. Полиморф по п.2, дополнительно характеризующийся термограммой дифференциальной сканирующей калориметрии (DSC), имеющей единственное максимальное значение при приблизительно 164 при измерении прибором Mettler 822e DSC.
6. Полиморф по любому из пп.1-5, полученный способом очистки, включающим стадию перекристаллизации сырого препарата указанной соли из ацетона.
7. Полиморф по п.6, причем количество указанного используемого ацетона составляет более чем 64 объема.
8. Фармацевтическая композиция, включающая полиморф по п.6 и фармацевтически приемлемый эксципиент или носитель.
9. Способ лечения или профилактики заболевания или состояния у пациента, включающий стадия введения указанному пациенту фармацевтической композиции по п.8, причем указанное заболевание или состояние выбраны из рака, потери слуха, остеопороза, ожирения, диабета, глазных заболеваний, инсульта, атеросклероза, нейропатической боли, гепатита B и аутоиммунного заболевания.
10. Способ получения полиморфа по любому из пп.1-5, включающий стадию добавления метансульфоновой кислоты к 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-N-бензилацетамиду в ацетоне.
11. Способ по п.10, в котором количество указанного ацетона составляет более чем 64 объема.
12. Способ по п.11, в котором количество указанного ацетона составляет более чем 64 и менее чем 100 объемов.
13. Способ по п.12, в котором количество указанного ацетона составляет 80 объемов.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/468,694 US7935697B2 (en) | 2006-12-28 | 2009-05-19 | Compositions for modulating a kinase cascade and methods of use thereof |
US12/468,694 | 2009-05-19 | ||
PCT/US2010/035408 WO2010135429A2 (en) | 2009-05-19 | 2010-05-19 | Compositions for modulating a kinase cascade and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2011151611A true RU2011151611A (ru) | 2013-06-27 |
RU2569299C2 RU2569299C2 (ru) | 2015-11-20 |
Family
ID=43126749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011151611/04A RU2569299C2 (ru) | 2009-05-19 | 2010-05-19 | Композиции для модуляции киназного каскада и способы их применения |
Country Status (5)
Country | Link |
---|---|
US (6) | US7935697B2 (ru) |
MY (1) | MY158648A (ru) |
RU (1) | RU2569299C2 (ru) |
SG (1) | SG176161A1 (ru) |
WO (1) | WO2010135429A2 (ru) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1836169T3 (pl) * | 2004-12-28 | 2012-07-31 | Kinex Pharmaceuticals Llc | Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek |
US7968574B2 (en) * | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
CN101595084B (zh) * | 2006-06-29 | 2013-01-02 | 金克斯医药品有限公司 | 用于调整激酶级联的二芳基组合物和方法 |
US20210198202A1 (en) * | 2006-12-28 | 2021-07-01 | Athenex, Inc. | Compositions for modulating a kinase cascade and methods of use thereof |
US7939529B2 (en) * | 2007-05-17 | 2011-05-10 | Kinex Pharmaceuticals, Llc | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof |
US7935697B2 (en) * | 2006-12-28 | 2011-05-03 | Kinex Pharmaceuticals, Llc | Compositions for modulating a kinase cascade and methods of use thereof |
US20100256147A1 (en) * | 2007-04-13 | 2010-10-07 | Hangauer Jr David G | Biaryl acetamide derivatives as modulators of the kinase cascade for the treatment of hearing loss, osteoporosis and cell proliferation disorders |
CA2703615C (en) * | 2007-10-20 | 2017-09-19 | Kinex Pharmaceuticals, Llc | Pharmaceutical compositions for modulating a kinase cascade and methods of use thereof |
US8735342B2 (en) | 2010-01-27 | 2014-05-27 | Neumedicines, Inc. | Method for treating brain cancer using a novel tumor suppressor gene and secreted factor |
WO2011129936A2 (en) | 2010-04-16 | 2011-10-20 | Kinex Pharmaceuticals, Llc | Compositions and methods for the prevention and treatment of cancer |
CN102250870B (zh) * | 2011-05-25 | 2013-09-04 | 青岛大学 | 实现热放大的量热法检测重金属用固定化酶的制作方法 |
US9926273B2 (en) | 2012-08-30 | 2018-03-27 | Athenex, Inc. | Composition and methods for modulating a kinase cascade |
EP3065757A4 (en) * | 2013-10-09 | 2017-08-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
CN108884130B (zh) | 2016-01-11 | 2022-09-13 | 博士医疗爱尔兰有限公司 | 用于治疗溃疡性结肠炎的制剂和方法 |
ES2914526T3 (es) | 2016-08-12 | 2022-06-13 | Athenex Inc | Composiciones de biarilo y métodos para modular una cascada de cinasa |
MX2019010707A (es) * | 2017-03-10 | 2020-01-15 | Athenex Inc | Metodos para tratar y/o prevenir queratosis actinica. |
AU2018325267B2 (en) * | 2017-09-01 | 2023-03-30 | University Of Washington | Crystalline forms of compounds for preventing or treating sensory hair cell death |
EP3679016A4 (en) | 2017-09-07 | 2021-09-29 | Athenex HK Innovative Limited | SOLID FORMS OF 2- (5- (4- (2-MORPHOLINOETHOXY) PHENYL) PYRIDINE-2-YL) -N-BENZYL ACETAMIDE |
CN109485599A (zh) * | 2019-01-16 | 2019-03-19 | 重庆迈德凯医药有限公司 | 一种Src酪氨酸激酶抑制剂晶型、其制备方法及药物组合物 |
JP2022535267A (ja) * | 2019-06-05 | 2022-08-05 | アセネックス インコーポレイテッド | 乾癬を治療および/または予防する方法 |
WO2022020114A2 (en) | 2020-07-10 | 2022-01-27 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
EP4302831A1 (en) | 2022-07-04 | 2024-01-10 | Trifarma S.p.A. | Process for synthesis of tirbanibulin |
CN115073362A (zh) * | 2022-08-04 | 2022-09-20 | 重庆迈德凯医药有限公司 | 一种替尼布林的合成方法 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3761477A (en) * | 1968-11-08 | 1973-09-25 | Mc Neil Labor Inc | Pyrazineacetic acids, lower alkyl esters, amides and salts |
IT1044222B (it) * | 1972-05-23 | 1980-03-20 | Zambeletti Spa L | Bifenilil alcanoilaminopiridine ad attivita anti infiammatoria di lunga durata |
AT341512B (de) * | 1975-01-09 | 1978-02-10 | Thomae Gmbh Dr K | Verfahren zur herstellung von neuen biphenylathern |
HU178253B (en) * | 1979-08-15 | 1982-04-28 | Gyogyszerkutato Intezet | Process for preparing 1,1,2-triphenyl-propane and -propane derivatives |
CA1261835A (en) | 1984-08-20 | 1989-09-26 | Masaaki Toda | (fused) benz(thio)amides |
JPS62252755A (ja) | 1986-04-11 | 1987-11-04 | Daikin Ind Ltd | 新規n−ベンジルベンズアミド誘導体およびこれを有効成分として含有する除草剤 |
US5232948A (en) | 1990-09-10 | 1993-08-03 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted monocyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity |
CH685875A5 (fr) | 1991-04-26 | 1995-10-31 | Pierre Baudet | Les N-phényl-benzamides protecteurs contre les effets nocifs de la lumière ultra-violette |
EP0613879A4 (en) | 1991-05-20 | 1995-05-03 | Tsumura & Co | PHELLODENDRIN ANALOGS AND TYPE IV ALLERGY SUPPRESSOR CONTAINING THEM AS ACTIVE INGREDIENTS. |
DE4236103A1 (de) | 1992-10-26 | 1994-04-28 | Hoechst Ag | Verfahren zur Kreuzkupplung von aromatischen Boronsäuren mit aromatischen Halogenverbindungen oder Perfluoralkylsulfonaten |
US5643957A (en) | 1993-04-22 | 1997-07-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
FR2705671B1 (fr) | 1993-05-26 | 1995-07-07 | Inst Nat Sante Rech Med | Nouveaux dérivés de l'hydroxybiphényle, leur préparation et les compositions pharmaceutiques qui les contiennent. |
CA2144669A1 (en) * | 1994-03-29 | 1995-09-30 | Kozo Akasaka | Biphenyl derivatives |
FR2737721B1 (fr) * | 1995-08-08 | 1997-09-05 | Roussel Uclaf | Nouveaux composes biphenyles, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicament et les compositions pharmaceutiques les contenant |
AU4885097A (en) | 1996-11-08 | 1998-06-03 | Sankyo Company Limited | Arylureas or arylmethylcarbamoyl derivatives |
ZA985542B (en) | 1997-07-03 | 1999-04-07 | Smithkline Beecham Corp | Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents |
JP2001023259A (ja) * | 1999-07-09 | 2001-01-26 | Sony Corp | 光磁気記録媒体およびその製造方法 |
US6844367B1 (en) * | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
WO2001019788A2 (en) | 1999-09-17 | 2001-03-22 | Cor Therapeutics, Inc. | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
US6372752B1 (en) | 2000-02-07 | 2002-04-16 | Genzyme Corporation | Inha inhibitors and methods of use thereof |
US20040039048A1 (en) | 2000-02-11 | 2004-02-26 | Manuel Guzman Pastor | Therapy with cannabinoid compounds for the treatment of brain tumors |
KR100423899B1 (ko) | 2000-05-10 | 2004-03-24 | 주식회사 엘지생명과학 | 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸 |
US6900232B2 (en) | 2000-06-15 | 2005-05-31 | Pharmacia Corporation | Cycloalkyl alkanoic acids as integrin receptor antagonists |
US6376524B1 (en) | 2000-06-21 | 2002-04-23 | Sunesis Pharmaceuticals, Inc. | Triphenyl compounds as interleukin-4 antagonists |
JP2002020362A (ja) | 2000-07-06 | 2002-01-23 | Nippon Oruganon Kk | 新規ビフェニル誘導体 |
CA2430037A1 (en) * | 2000-11-20 | 2002-05-30 | Michael S. South | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
EP1373257B9 (en) | 2001-03-29 | 2008-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
DE10201764A1 (de) | 2002-01-18 | 2003-07-31 | Bayer Cropscience Ag | Substituierte 4-Aminopyridin-Derivate |
JP2003231633A (ja) | 2002-02-06 | 2003-08-19 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
US20050027016A1 (en) | 2002-02-07 | 2005-02-03 | Fahl Kathleen L | Polyamine compounds and compositions for use in conjection with cancer therapy |
CA2473505A1 (en) | 2002-02-07 | 2003-08-14 | Ellen M. Leahy | Novel bicyclic hydroxamates as inhibitors of histone deacetylase |
FR2836917B1 (fr) | 2002-03-11 | 2006-02-24 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
DE10219294A1 (de) | 2002-04-25 | 2003-11-13 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
GB0209891D0 (en) | 2002-04-30 | 2002-06-05 | Glaxo Group Ltd | Novel compounds |
AU2003234464B2 (en) | 2002-05-03 | 2009-06-04 | Exelixis, Inc. | Protein kinase modulators and methods of use |
PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
SE0201937D0 (sv) | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | Therapeutic agents |
AU2003254177A1 (en) | 2002-07-31 | 2004-02-16 | Smithkline Beecham Corporation | Substituted benzanilides as modulators of the ccr5 receptor |
AU2003250701A1 (en) | 2002-07-31 | 2004-02-16 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
WO2004014279A2 (en) | 2002-08-07 | 2004-02-19 | Mauro Xavier | Stretching lumbar-sacral floating (slsf) vest |
NZ538715A (en) | 2002-08-14 | 2007-07-27 | Vertex Pharma | Protein kinase inhibitors and uses thereof |
US20040242572A1 (en) * | 2002-08-24 | 2004-12-02 | Boehringer Ingelheim International Gmbh | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture |
DE10238865A1 (de) | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
CA2506772A1 (en) | 2002-11-01 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of jak and other protein kinases |
ATE343583T1 (de) | 2002-11-08 | 2006-11-15 | Novo Nordisk As | Halogensulfonylarylboronate |
ATE552253T1 (de) | 2002-11-08 | 2012-04-15 | Novartis Int Pharm Ltd | 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren |
US8030336B2 (en) | 2002-12-13 | 2011-10-04 | Ym Biosciences Australia Pty Ltd | Nicotinamide-based kinase inhibitors |
CA2510471A1 (en) * | 2002-12-19 | 2004-07-08 | Neurogen Corporation | Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators |
UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
US7732608B2 (en) | 2003-04-25 | 2010-06-08 | Cadila Healthcare Limited | Salts of clopidogrel and process for preparation |
SG2009082793A (en) * | 2003-06-03 | 2015-03-30 | Rib X Pharmaceuticals Inc | Biaryl heterocyclic compounds and methods of making and using the same |
WO2005014532A1 (en) * | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
EP2332912A1 (en) | 2003-08-08 | 2011-06-15 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenylderivates for use as sodium or calcium channel blockers in the treatment of pain |
US20050197364A1 (en) | 2003-10-07 | 2005-09-08 | Kelly Michael G. | Amide compounds as ion channel ligands and uses thereof |
EP2314576A1 (en) | 2003-11-05 | 2011-04-27 | F.Hoffmann-La Roche Ag | Phenyl derivatives as PPAR agonists |
PE20060285A1 (es) | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
CA2575928A1 (en) | 2004-08-02 | 2006-02-09 | Genmedica Therapeutics Sl | Compounds for inhibiting copper-containing amine oxidases and uses thereof |
US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
PL1836169T3 (pl) | 2004-12-28 | 2012-07-31 | Kinex Pharmaceuticals Llc | Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek |
KR20080040027A (ko) | 2005-09-02 | 2008-05-07 | 아스테라스 세이야쿠 가부시키가이샤 | Rock 억제제로서 아미드 유도체 |
WO2007095383A2 (en) | 2006-02-15 | 2007-08-23 | Myriad Genetics, Inc. | Prodrugs |
CA2651732C (en) | 2006-05-18 | 2014-10-14 | Mannkind Corporation | Intracellular kinase inhibitors |
DK2041071T3 (da) | 2006-06-29 | 2014-09-01 | Kinex Pharmaceuticals Llc | Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade |
CN101595084B (zh) | 2006-06-29 | 2013-01-02 | 金克斯医药品有限公司 | 用于调整激酶级联的二芳基组合物和方法 |
US20100210649A1 (en) | 2006-12-21 | 2010-08-19 | Sloan-Kettering Institute For Cancer Research | Pyridazinones and furan-containing compounds |
TWI457336B (zh) * | 2006-12-28 | 2014-10-21 | Kinex Pharmaceuticals Llc | 調節激酶級聯之組成物及方法 |
US7939529B2 (en) * | 2007-05-17 | 2011-05-10 | Kinex Pharmaceuticals, Llc | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof |
US7935697B2 (en) * | 2006-12-28 | 2011-05-03 | Kinex Pharmaceuticals, Llc | Compositions for modulating a kinase cascade and methods of use thereof |
US20100256147A1 (en) | 2007-04-13 | 2010-10-07 | Hangauer Jr David G | Biaryl acetamide derivatives as modulators of the kinase cascade for the treatment of hearing loss, osteoporosis and cell proliferation disorders |
US8124605B2 (en) | 2007-07-06 | 2012-02-28 | Kinex Pharmaceuticals, Llc | Compositions and methods for modulating a kinase cascade |
CA2703615C (en) | 2007-10-20 | 2017-09-19 | Kinex Pharmaceuticals, Llc | Pharmaceutical compositions for modulating a kinase cascade and methods of use thereof |
WO2011129936A2 (en) | 2010-04-16 | 2011-10-20 | Kinex Pharmaceuticals, Llc | Compositions and methods for the prevention and treatment of cancer |
US9926273B2 (en) | 2012-08-30 | 2018-03-27 | Athenex, Inc. | Composition and methods for modulating a kinase cascade |
-
2009
- 2009-05-19 US US12/468,694 patent/US7935697B2/en active Active
-
2010
- 2010-05-19 RU RU2011151611/04A patent/RU2569299C2/ru active
- 2010-05-19 SG SG2011085339A patent/SG176161A1/en unknown
- 2010-05-19 MY MYPI2011005540A patent/MY158648A/en unknown
- 2010-05-19 WO PCT/US2010/035408 patent/WO2010135429A2/en active Application Filing
-
2011
- 2011-04-26 US US13/094,679 patent/US8309549B2/en active Active
-
2012
- 2012-09-13 US US13/614,063 patent/US8901297B2/en active Active
-
2014
- 2014-11-26 US US14/554,495 patent/US9556120B2/en active Active
-
2016
- 2016-12-21 US US15/387,322 patent/US10323001B2/en active Active
-
2019
- 2019-04-30 US US16/398,420 patent/US20190256468A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20170101378A1 (en) | 2017-04-13 |
US20130210822A1 (en) | 2013-08-15 |
US20110201612A1 (en) | 2011-08-18 |
WO2010135429A3 (en) | 2011-03-31 |
SG176161A1 (en) | 2011-12-29 |
US20150315147A1 (en) | 2015-11-05 |
US10323001B2 (en) | 2019-06-18 |
RU2569299C2 (ru) | 2015-11-20 |
US8309549B2 (en) | 2012-11-13 |
US20090318450A1 (en) | 2009-12-24 |
WO2010135429A8 (en) | 2011-06-03 |
US8901297B2 (en) | 2014-12-02 |
WO2010135429A2 (en) | 2010-11-25 |
US7935697B2 (en) | 2011-05-03 |
MY158648A (en) | 2016-10-31 |
US9556120B2 (en) | 2017-01-31 |
US20190256468A1 (en) | 2019-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2011151611A (ru) | Композиции для модуляции киназного каскада и способы их применения | |
AU2018396402C1 (en) | Nitrogen-containing 6-membered cyclic compound | |
NZ627750A (en) | Carbamate compounds and of making and using same | |
BRPI0924126A2 (pt) | composto heterocíclico bicíclico | |
EP2968287A2 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
KR20140117498A (ko) | 다중고리 유도체들, 제조 방법 그리고 그것들의 약제 용도 | |
NZ587518A (en) | Crystalline form III of (3,5-bis trifluoromethyl)-N-[4-methyl-3-({ 4-(pyridin-3 yl)-pyrimidin-2-yl} amino)-phenyl]-benzamide | |
CA2656057A1 (en) | Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain | |
CA2798168A1 (en) | Polysubstituted benzofurans and medicinal applications thereof | |
WO2012090219A2 (en) | Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors | |
RU2013130878A (ru) | Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx | |
JP2021508318A (ja) | チューブリン阻害剤 | |
EA035989B1 (ru) | Кристаллические формы и способы получения модуляторов каннабиноидного рецептора | |
RU2013103754A (ru) | Новые кристаллические формы n-[-2[[(2,3,-дифторфенил)метил]тио]-6-{[(1r, 2s)-2,3-дигидрокси-1-метилпропил]окси}-4-пиримидинил]-1-азатидин-сульфонамида | |
JP2010053115A (ja) | 新規フェニルアセテート誘導体またはその薬学的に許容可能な塩、その製造方法及びそれを有効成分として含むt−型カルシウムイオンチャンネルの活性によって誘発される疾患の予防または治療用組成物 | |
JP2010504321A5 (ru) | ||
RU2012136921A (ru) | Твердые формы, содержащие производные циклопропиламида | |
CN103204816B (zh) | 哌嗪基嘧啶类衍生物及其制备方法和用途 | |
EA201270217A1 (ru) | Замещенные бензамидные производные в качестве активаторов глюкокиназы (гк) | |
CN106232116B (zh) | 含有香豆素衍生物作为有效成分的治疗或预防剂 | |
DK3006443T3 (en) | benzothiophene | |
JP6569678B2 (ja) | 2−アミノチアゾール誘導体またはその塩 | |
WO2014046224A1 (ja) | クマリン誘導体 | |
JP2020517676A5 (ru) | ||
WO2013047719A1 (ja) | 2-(ピリジン-2-イル)ピリミジン-4-アミン化合物又はその塩 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HZ9A | Changing address for correspondence with an applicant |